Kairos Technologies

 

Unmet Medical Need

Drug

How Kairos Addresses Unmet Medical Need

Development of resistance to many, otherwise effective cancer drugs

ENV 105

• ENV 105 inhibits CD105  (CD105 is the protein responsible for cancer drug resistance in various forms of cancer)

• Currently in Phase 2 trial in prostate cancer and Phase 1 trial in lung cancer

T cells drastically reduced by cancer

 

KROS 101

• KROS 101 uses a novel dual mechanism to increase killer T effector cells and reduce suppressor T reg cells  (T cells have 2 types cells: those that kill cancer cells and those that inhibit the killer T cell response)

In autoimmune diseases, T cells are overactive against normal cells

KROS 102

• KROS 102 has the opposite effect of KROS101, by decreasing the number of  overactive T effector cells and increasing T reg suppressor cells

Immunosuppression from cancer

KROS 201

• KROS 201 are  killer T effector cells generated outside of the immunosuppressed body which will be delivered to cancer cells to kill cancer stem cells that drive cancer growth.

• Currently cleared for IND (investigational new drug application) by FDA

Chemotherapies are untargeted and immunosuppressive

KROS 301

• KROS 301 kills tumor cells while leaving normal cells unscathed by targeting the NF-kB molecular pathway. KROS 301 also inhibits the mechanism of PD-L1 expression on tumor cells (PD-L1 is a “checkpoint inhibitor” that prevents T cells from killing the cancer)

Tumor environment is immunosuppressive from macrophages (a type of white cell that can be either anti-cancer or pro-cancer)

KROS 401

• KROS 401 targets pro-cancer macrophages to convert them into anti-cancer macrophages

Development of resistance to various specific chemotherapies

ENV 205

• ENV 205 targets & expels mitochondrial DNA that are released by tumors which use this mechanism of resistance against specific chemotherapies